Spineart Group revenues increased 34.5% for the second quarter 2019 and 28% for the first half of 2019. Company growth is well balanced among all the product lines and geographical areas. The US market represented 43% of Spineart’s revenues for the second quarter and 42% for the first half of 2019.
Spineart USA Inc. reported record second quarter and half-year revenues. Revenues increased 74% (60% in constant currency) for the quarter and 54% (43% in constant currency) for the first half of 2019.
Revenues from interbodies incorporating Ti-LIFE Technology, a proprietary 3D-printed trabecular structure, grew 176% (156% in constant currency) for the first half of 2019.
In 2019, Spineart USA was selected as one of only six authorized vendors for spinal implants within the Providence Health System, one of the largest integrated delivery networks in the country.
In the second part of the year, Spineart USA will proceed with the full commercial release of SCARLET AL-T, its secured anterior lumbar titanium cage with Ti-LIFE Technology.
Thus far in 2019, Spineart has received four new 510(k) clearances from the FDA.